Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

Supportive Care in Cancer

Volumn 17, Issue 8, 2009, Pages 1065-1070

  Hesketh, Paul J ^a   Younger, Jerry ^b   Sanz Altamira, Pedro ^c   Hayden, Melissa ^b   Bushey, Julie ^c   Trainor, Brian ^a   Krentzin, Michael ^a   Nowd, Peter ^a   Arnaoutakis, Konstantinos ^a   Hesketh, Ann M ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Caritas Holy Family Hospital   (United States)

Author keywords

Antiemetic; Aprepitant; Breast cancer; Nausea; Vomiting

Indexed keywords

EID: 72249106951     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-008-0545-7     Document Type: Article

References (25)

1. 3 antagonists. Br J Cancer 76:1055-1061
2. Hickok JT, Roscoe JA, Morrow GR et al (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880-2886 doi:10.1002/cncr.11408
3. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis: definition and validation of a predictive logistic model. Cancer 64:1117-1122 doi:10.1002/1097-0142(19890901)64:5<1117::AID- CNCR2820640525>3.0.CO;2-R
4. du Bois A, Meerpohl HG, Vach W et al (1992) Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatinpretreated patients: a study with ondansetron. Eur J Cancer 28:450-457 doi:10.1016/S0959-8049(05)80075- 9
5. Hesketh P, Navari R, Grote T et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249
6. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
7. DiBenedetto J Jr, Cubeddu LX, Ryan T et al (1995) Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther 17:1091-1098 doi:10.1016/0149-2918(95)80087-5
8. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
9. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy- induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119 doi:10.1200/JCO.2003.01.095
10. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 97:3090-3098 doi:10.1002/cncr.11433
11. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, (Erratum, J Clin Oncol 2005; 23:5851) doi:10.1200/JCO.2005. 09.050
12. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-2494 doi:10.1056/NEJMra0706547
13. Perez EA (1999) 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 57:207-214 doi:10.1023/A:1006233802863
14. Beck TM, Ciociola AA, Jones SE et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann Intern Med 118:407-413
15. Hesketh PJ (1994) Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 2:286-292 doi:10.1007/BF00365579
16. Hesketh PJ (2000) Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18:163-173 doi:10.3109/07357900009038248
17. Roila F, Hesketh PJ, Herrstedt J et al (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28 doi:10.1093/annonc/mdj936
18. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947, (Erratum, J Clin Oncol 2006; 24:5341-5342) doi:10.1200/JCO.2006.06.9591
19. Ettinger DS, Bierman PJ, Bradbury B et al (2007) Antiemesis. J Natl Compr Canc Netw 5:12-33
20. Herrstedt J (2007) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 18 (Suppl 2):ii83-ii85 doi:10.1093/annonc/mdm050
21. Vermeulen LC Jr, Matuszewski KA, Ratko TA et al (1994) Evaluation of ondansetron prescribing in US academic medical centers. Arch Intern Med 154:1733-1740 doi:10.1001/archinte.154.15.1733
22. Fabi A, BarduagniM, Lauro S et al (2003) Is delayed chemotherapyinduced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156-161
23. Drug Utilization Review Team in Oncology (DURTO) (2003) Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 11:785-789 doi:10.1007/s00520-003-0478-0
24. Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6:622-625 doi:10.1016/S1470-2045(05)70284-9
25. Oechsle K, Muller M, Hartmann J et al (2006) Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 29:557-561 doi:10.1159/000096689